synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Malta === The Parliament of Malta consists of the president of Malta and the House of Representatives of 69 members (article 51 of the Constitution), referred to as "members of Parliament" (article 52(1) of the Constitution). When appointed from outside the House, the speaker is also considered a member of the Parliament. The Constitution lists the qualifications and disqualifications from serving as a member of Parliament. Privileges of members of Parliament and their Code of Ethics are laid out in the House of Representatives (Privileges and Powers) Ordinance.
This mutation causes fewer GAG chains to be added to HSPGs and CSPGs, meaning there are fewer complexes available to closely regulate the maturation of chondrocytes. Incorrect signals are sent to chondrocytes in the cartilage anlage because the GAG chain and proteoglycan complexes are unable to work properly and cause the chondrocytes to mature and ossify too quickly. The correct amount of chondrocytes are not able to gather in the cartilage anlage, leading to a shortage of cartilage for ossification and eventually shorter bones. While the pug mutation deals with the pre-maturation of chondrocytes, multiple other mutations alter chondrocyte proliferation. One such example, the point mutation G380R located on the fibroblast growth factor receptor 3 (FGFR-3) gene leads to achondroplasia, a type of dwarfism. Achondroplasia is either caused through a spontaneous mutation or inherited in an autosomal dominant fashion. Both the homozygous dominant and the heterozygous genotypes exhibit achondroplasia symptoms, but the heterozygotes are often milder. Individuals with the mutated allele(s) display a variety of symptoms of the failure of endochondral ossification, including the shortening of proximal long limbs and midface hypoplasia. The non-mutated FGFR-3 gene is responsible for the expression of fibroblast growth factors (FGFs) which has to maintain a certain level to ensure that the proliferation of chondrocytes happens accordingly. The G380R mutation causes FGFR-3 to over express FGFs and the balance within the cartilage extracellular matrix is thrown off.
15 September – The Sunday Times reports that Starmer may have broken parliamentary rules by failing to declare clothes bought for his wife, Victoria, by Labour donor Lord Waheed Alli. 16 September – Downing Street confirms that the Parliamentary Commissioner on Standards will not investigate whether Starmer broke parliamentary rules by not declaring a gift of clothes for his wife. The Welsh Government scraps plans to force parties in the Senedd to ensure 50% of their candidates are women. 18 September – Liberal Democrat leader Ed Davey unveils an expanded 33-member frontbench team following the party's gains at the general election. Former prime minister Sir John Major criticises the Sunak government's Rwanda asylum plan, describing it as "un-Conservative and un-British". Ofcom announces it will not investigate Ed Balls' interview with his wife, Home Secretary Yvette Cooper, on Good Morning Britain on 5 August despite receiving over 16,000 viewer complaints. ITV chief executive Dame Carolyn McCall defends the interview's impartiality, but says the broadcaster would not do it again. 20 September – Downing Street confirms that Keir Starmer, Angela Rayner and Rachel Reeves will no longer accept donations for clothing following controversy over gifts given to Starmer's wife. 22–25 September – The 2024 Labour Party Conference is scheduled to take place at the ACC Liverpool. 24 September – Starmer gives his keynote conference speech, setting out plans for "national renewal" but telling delegates there are no "easy answers".
=== Toxicity === There are two aspects to the harmful effects of plutonium: radioactivity and heavy metal poisoning. Plutonium compounds are radioactive and accumulate in bone marrow. Contamination by plutonium oxide has resulted from nuclear disasters and radioactive incidents, including military nuclear accidents where nuclear weapons have burned. Studies of the effects of these smaller releases, as well as of the widespread radiation poisoning sickness and death following the atomic bombings of Hiroshima and Nagasaki, have provided considerable information regarding the dangers, symptoms and prognosis of radiation poisoning, which in the case of the Japanese survivors was largely unrelated to direct plutonium exposure. The decay of plutonium, releases three types of ionizing radiation: alpha (α), beta (β), and gamma (γ). Either acute or longer-term exposure carries a danger of serious health outcomes including radiation sickness, genetic damage, cancer, and death. The danger increases with the amount of exposure. α-radiation can travel only a short distance and cannot travel through the outer, dead layer of human skin. β-radiation can penetrate human skin, but cannot go all the way through the body. γ-radiation can go all the way through the body. Even though α radiation cannot penetrate the skin, ingested or inhaled plutonium does irradiate internal organs. α-particles generated by inhaled plutonium have been found to cause lung cancer in a cohort of European nuclear workers.
=== Meningitis === Blood procalcitonin levels can help confirm bacterial meningitis and, if negative, can effectively rule out bacterial meningitis. This was shown in a review of over 2000 patients in which PCT had a sensitivity of 86% and a specificity of 80% for cerebrospinal fluid PCT. Blood PCT measurements proved superior to cerebrospinal fluid PCT with a sensitivity of 95% and a specificity of 97% as a marker for bacterial meningitis. In acute meningitis, serum PCT is useful as a biomarker for sepsis. It can also be of use in determining viral meningitis versus bacterial meningitis. These findings are the result of a 2018 literature review. This followed a 2015 meta analysis that showed that PCT had a sensitivity of 90% and a specificity of 98% in judging viral versus bacterial meningitis. PCT also outperformed other biomarkers such as C-reactive protein.
Sources: en.wikipedia.org
Fever and Taking Your Child's Temperature US National Institute of Health factsheet Drugs most commonly associated with the adverse event Pyrexia (Fever) as reported the FDA Archived 9 March 2012 at the Wayback Machine Fever at MedlinePlus Why are We So Afraid of Fevers? at The New York Times
=== Applications in marketing and advertising === Industry standards now cover AI agents that plan, negotiate, and buy digital media. In 2026, the technology arm of the Interactive Advertising Bureau, IAB Tech Lab, published the Agentic Advertising Management Protocols (AAMP), an open framework for agents that discover inventory, negotiate, and complete media transactions on behalf of buyers and sellers. This differs from platform-native automation such as Google Ads Smart Bidding and Meta Advantage+, which optimize bids and delivery inside a single advertising platform. Cross-channel agents instead recommend budget changes across media, typically with a human in the loop.
Animals and plants have evolved to synthesise a vast array of poisonous products including secondary metabolites, peptides and proteins that can act as inhibitors. Natural toxins are usually small organic molecules and are so diverse that there are probably natural inhibitors for most metabolic processes. The metabolic processes targeted by natural poisons encompass more than enzymes in metabolic pathways and can also include the inhibition of receptor, channel and structural protein functions in a cell. For example, paclitaxel (taxol), an organic molecule found in the Pacific yew tree, binds tightly to tubulin dimers and inhibits their assembly into microtubules in the cytoskeleton. Many natural poisons act as neurotoxins that can cause paralysis leading to death and function for defence against predators or in hunting and capturing prey. Some of these natural inhibitors, despite their toxic attributes, are valuable for therapeutic uses at lower doses. An example of a neurotoxin are the glycoalkaloids, from the plant species in the family Solanaceae (includes potato, tomato and eggplant), that are acetylcholinesterase inhibitors. Inhibition of this enzyme causes an uncontrolled increase in the acetylcholine neurotransmitter, muscular paralysis and then death. Neurotoxicity can also result from the inhibition of receptors; for example, atropine from deadly nightshade (Atropa belladonna) that functions as a competitive antagonist of the muscarinic acetylcholine receptors.
=== Immediate effects === Users report feelings of relaxation, sharpness, calmness, and alertness. Those new to smoking may experience nausea, dizziness, coughing and a bad taste in the mouth, and a number of adverse cardio-vascular effects such as increased blood pressure, narrowed arteries, rapid heart beat. Generally, the unpleasant symptoms will eventually vanish over time, with repeated use, as the body builds a tolerance to the chemicals in the cigarettes, such as nicotine. While the functional changes are mostly reversible after quitting, the structural cardiovascular damage is not fully reversible.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.